More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of ...

Although most models of transporter function have assumed that they function as single subunits, early studies using radiation inactivation indicated that monoamine transporters might exist as ...

Panel D depicts the vesicular monoamine transporter 2 (VMAT2) protein within the synaptic vesicle membrane; the arrow indicates the mutated proline. Panel E shows the primary sequence of the ...

One goal of our research is to enhance our understanding of how drugs of abuse, antidepressants, and other small molecules interact with and modulate the function of monoamine transporters (MATs), ...

Scientists at St. Jude Children's Research Hospital have drawn on structural biology expertise to determine structures of vesicular monoamine transporter 2 (VMAT2), a key component of neuronal ...

Austedo and Austedo XR are vesicular monoamine transporter 2 (VMAT2) inhibitors (has a blocking action), not antipsychotic drugs. (“XR” stands for “extended release.” This means the drug ...

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences , 2014; DOI: 10 ...

Monoamine oxidase A (MAO-A ... polymorphisms of the serotonin-reuptake transporter associated with depression, an inadequate response of G proteins to neurotransmitter signals, and reduced ...

Noradrenaline (NA) is an important monoamine neurotransmitter in the nervous system. The noradrenaline transporter (NET) located on the presynaptic membrane can transport NA into presynaptic neurons.

Austedo contains the active ingredient deutetrabenazine. It belongs to a group of drugs called vesicular monoamine transporter 2 (VMAT2) inhibitors. It’s not available as a generic drug.